Empagliflozin suppresses inflammation and protects against acute septic renal injury
Author:
Funder
CIHR
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Immunology
Link
https://link.springer.com/content/pdf/10.1007/s10787-020-00732-4.pdf
Reference39 articles.
1. Alvarez CA, Neeland IJ, McGuire DK (2015) Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the pot. Diabetes Vasc Dis Res 12:74–77. https://doi.org/10.1177/1479164114563303
2. Bagshaw SM et al (2007) Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2:431–439. https://doi.org/10.2215/CJN.03681106
3. Benetti E et al (2016) Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation. J Pharmacol Exp Ther 359:45–53. https://doi.org/10.1124/jpet.116.235069
4. Bhavsar SK et al (2016) Expression of JAK3 sensitive Na+ coupled glucose carrier SGLT1 in activated cytotoxic T lymphocytes. Cell Physiol Biochem 39:1209–1228. https://doi.org/10.1159/000447827
5. Butler J et al (2019) Empagliflozin improves kidney outcomes in patients with or without heart failure circulation. Heart Fail 12:e005875. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005875
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials;The Lancet Diabetes & Endocrinology;2024-09
2. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial;The Lancet Diabetes & Endocrinology;2024-09
3. Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction;JAMA;2024-08-06
4. SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice;International Journal of Molecular Sciences;2024-07-10
5. Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis;Frontiers in Pharmacology;2024-06-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3